GLPwatch
Papers (10373)
Page 49 of 173, ranked by citation count.
- Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.
- Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
- Calcium/calmodulin-dependent serine protein kinase is involved in exendin-4-induced insulin secretion in INS-1 cells.
- GLP-1RA promotes brown adipogenesis of C3H10T1/2 mesenchymal stem cells via the PI3K-AKT-mTOR signaling pathway.
- The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
- Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist.
- Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA.
- GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
- Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
- Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.
- PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
- Time for testing incretin therapies in early type 1 diabetes?
- Birth and death of human β-cells in pancreases from cadaver donors, autopsies, surgical specimens, and islets transplanted into mice.
- Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury.
- Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
- Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet.
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.
- Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway.
- Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
- Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
- Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity.
- Is insulin the most effective injectable antihyperglycaemic therapy?
- Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice.
- The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.
- Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
- Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness.
- Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.
- The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function.
- Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
- Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.
- The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats.
- Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
- PNPLA3 Risk Allele Association With ALT Response to Semaglutide Treatment.
- Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice.
- GLP-1 analog liraglutide enhances proinsulin processing in pancreatic β-cells via a PKA-dependent pathway.
- Dermatologic findings associated with semaglutide use: A scoping review.
- The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.
- Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
- Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.
- Incretin-based therapies for the treatment of obesity-related diseases.
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.
- Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.
- Nephrotoxicity in mice after repeated imaging using 111In-labeled peptides.
- Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists.
- Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
- Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
- Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss.
- Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
- Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
- Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy.
- Uncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging.
- GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?
- Species differences in pancreatic binding of DO3A-VS-Cys<sup>40</sup>-Exendin4.
- Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
- Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats.
- Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
- Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
- The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes.
- Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes.